Ebert started his career as a Harvard Medical School faculty member at
Brigham and Women's Hospital, where he led an independent research laboratory and practiced medicine as a hematologist/oncologist. His laboratory described the genomic landscape of adult myelodysplastic syndromes and identified RPS14 as a key gene for deletion 5q MDS. In 2014, Ebert's lab found that
lenalidomide, a cancer drug, targeted two proteins, IKZF1 and IKZF3, for degradation. This finding and additional studies established the mechanism of action of lenalidomide in both multiple myeloma and del(5q) MDS. An independent line of investigation characterized and defined clonal hematopoiesis of indeterminate potential (CHIP) as a precursor state for blood cancers and a risk factor for inflammatory diseases. As a result of his research, Ebert was the recipient of the 2017 William Dameshek Prize from the
American Society of Hematology. In 2017, Ebert moved to Dana-Farber Cancer Institute to be Chair of the Department of Medical Oncology. In 2018, Ebert, was elected a member of the
National Academy of Medicine for his "contributions to understanding the genetics and biology of myeloid malignancies, to the characterization of clonal hematopoiesis, and for elucidating the mechanism of action of thalidomide and its analogs." He was named a
Howard Hughes Medical Institute Investigator in 2019. He has received multiple recognitions for mentorship including the Thomas McMahon Award and the Seidman Prize from the HST Program at Harvard Medical School. == Awards ==